WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 5'5501 Infant (under 12 months) mortality rate: 452
GDP / capita (US$): 10'5831 Child (under 5 years) mortality rate: 532

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 5'173  5'107  5'042  4'979  4'918  4'501  3'668  2'861 
Births 111  111  110  109  109  107  130  99 
Surviving infants 106  105  105  104  103  101  120  90 
Pop. less than 5 years 503  500  506  508  518  490  579  437 
Pop. less than 15 years 1'477  1'469  1'474  1'480  1'497  1'634  1'484  1'182 
Female 15-49 years 1'476  1'463  1'445  1'426  1'401  1'193  875  661 

Number of reported case

(Click for retrospective incidence data for Turkmenistan)
Diphtheria 11  30 
Japanese encephalitis
Measles 113  2'806 
Mumps 31  61  143  241  1'124 
Pertussis 11  260 
Polio*
Rubella 129 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Turkmenistan)
Vaccine year result method % card seen                                                
BCG 1994  92  MICS     99  98  99  99  99  99 
DTP1          98  98  99  99  98  97 
DTP3 1994  82  MICS     97  97  96  97  96  97 
HepB_BD          100  100  100  100  100 
HepB3          98  97  96  97  96 
Hib3          97  71  58 
JapEnc         
MCV 1994  76  MICS     99  99  99  99  99  97 
MCV2          99  99  99  99  99  92 
PCV1         
PCV3         
Pol3 1994  86  MICS     98  97  96  97  96  98 
Rota1         
Rota_last         
Rubella1          99  99  99  99 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Turkmenistan)
BCG 99  98  99  99  99  99 
DTP1 98  98  99  98  98  97 
DTP3 97  97  96  96  96  97 
HepB3 98  97  96  97  96 
Hib3 97  71  58 
MCV 99  99  99  99  99  96 
PCV3
Pol3 98  97  96  97  96  98 
Rota_last

Number of districts in the country 67  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; 14 years; Yes
DT 6 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 2, 3, 4 months; Yes
HepB birth; Yes
MMR 12 months; 6 years; Yes
OPV 2 days; 2, 3, 4, 18 months; Yes
Td 15, 25 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes    Yes 
What years does the MYP cover? number 2003-2020  2003-2020  2003-2020  Yes      2003-2020 
Nº of districts with microplans that include activities to raise immunization coverage number 67  67    61  61     

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR No  NA           

System performance

Total number of districts in country number 67  67  64  64  61  61  61 
Nº districts with DTP3 coverage >=80% number 67  67  64  64  61    61 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100    100 
Nº districts with measles (MCV1) coverage >=95% number 67  67  64  64  60     
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  98     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes           

Finance

Percentage of routine vaccines funded by Government From 0 to 100%           77  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.